125 related articles for article (PubMed ID: 20508581)
1. Romidepsin (Istodax) for cutaneous T-cell lymphoma.
Med Lett Drugs Ther; 2010 May; 52(1339):42-3. PubMed ID: 20508581
[No Abstract] [Full Text] [Related]
2. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
Lyseng-Williamson KA; Yang LP
Am J Clin Dermatol; 2012 Feb; 13(1):67-71. PubMed ID: 22066664
[TBL] [Abstract][Full Text] [Related]
3. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH
J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094
[TBL] [Abstract][Full Text] [Related]
4. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M
Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
[TBL] [Abstract][Full Text] [Related]
5. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma.
Samimi S; Morrissey K; Anshelevich S; Evans K; Gardner J; Musiek A; Vittorio C; Rook A; Kim E
J Am Acad Dermatol; 2013 Jan; 68(1):e5-6. PubMed ID: 23244387
[No Abstract] [Full Text] [Related]
6. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
[TBL] [Abstract][Full Text] [Related]
7. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
Akilov OE; Grant C; Frye R; Bates S; Piekarz R; Geskin LJ
Br J Dermatol; 2012 Jul; 167(1):194-7. PubMed ID: 22372971
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin for the treatment of cutaneous T-cell lymphoma.
Campas-Moya C
Drugs Today (Barc); 2009 Nov; 45(11):787-95. PubMed ID: 20126671
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
[TBL] [Abstract][Full Text] [Related]
10. Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.
Nat Rev Drug Discov; 2010 Feb; 9(2):94. PubMed ID: 20118955
[No Abstract] [Full Text] [Related]
11. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.
Kim EJ; Kim YH; Rook AH; Lerner A; Duvic M; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Waksman J; Whittaker S
Leuk Lymphoma; 2015; 56(10):2847-54. PubMed ID: 25791237
[TBL] [Abstract][Full Text] [Related]
12. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.
Kim YH; Demierre MF; Kim EJ; Lerner A; Rook AH; Duvic M; Robak T; Samtsov A; McCulloch W; Chen SC; Waksman J; Nichols J; Whittaker S
Leuk Lymphoma; 2013 Feb; 54(2):284-9. PubMed ID: 22839723
[TBL] [Abstract][Full Text] [Related]
13. Future directions for pentostatin (Nipent) usage in dermatology.
Heald P
Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
[TBL] [Abstract][Full Text] [Related]
14. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
Kim M; Thompson LA; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
[TBL] [Abstract][Full Text] [Related]
15. New drugs: pitavastatin calcium, vigabatrin, and romidepsin.
Hussar DA; Christian ME
J Am Pharm Assoc (2003); 2010; 50(4):548-51. PubMed ID: 20621877
[No Abstract] [Full Text] [Related]
16. Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma.
Bashey S; Krathen M; Abdulla F; Sundram U; Kim YH
J Clin Oncol; 2012 Aug; 30(24):e221-5. PubMed ID: 22753921
[No Abstract] [Full Text] [Related]
17. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity to romidepsin.
Kakar R; Rommel J; McKinley-Grant L; Shenoy AG; DeSimone JA
J Am Acad Dermatol; 2014 Jan; 70(1):e21-2. PubMed ID: 24355282
[No Abstract] [Full Text] [Related]
19. Romidepsin: in the treatment of T-cell lymphoma.
Yang LP
Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Woo S; Gardner ER; Chen X; Ockers SB; Baum CE; Sissung TM; Price DK; Frye R; Piekarz RL; Bates SE; Figg WD
Clin Cancer Res; 2009 Feb; 15(4):1496-503. PubMed ID: 19228751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
